BioAmber Inc. announced unaudited consolidated earnings results for the second quarter ended June 30, 2017. For the quarter, the company's revenue for the quarter ended June 30, 2017 were $4.1 million, an increase of 64% over the previous quarter, mainly driven by growth in succinic acid volume sold, slightly offset by a decrease in average selling price. The company recorded a net loss attributable to company shareholders of $7.1 million, or a loss of $0.20 per share, for the quarter ended June 30, 2017, compared to a net income of $4.8 million, or an income of $0.17 per share, for the same period last year. The adjusted net loss attributable to company shareholders for the quarter ended June 30, 2017 was $7.3 million, or a loss of $0.20 per share, compared to an adjusted net loss attributable to company shareholders of $7.1 million, or a loss of $0.25 per share, for the three months ended June 30, 2016. Operating loss was $7,802,000 compared to $7,315,000 a year ago. Loss before income taxes was $8,849,000 compared to income before income tax of $2,945,000 a year ago. Net cash used in operating activities was $18,765,000 compared to $25,675,000 a year ago. Acquisition of property and equipment and intangible asset, net of disposals was $426,000 compared to $364,000 a year ago.